Three antidepressants may offer better long-term relief from depression symptoms than a commonly prescribed medication, according to new research. The findings highlight escitalopram, agomelatine, and duloxetine as promising options for maintaining improvements in people living with depression.
The research, discussed in a November 2026 report by Medical News Today, examined the long-term effectiveness of different antidepressant medications. Researchers compared 20 medications against fluoxetine, a widely recognized antidepressant. Their findings suggest that some medications may provide more sustained symptom improvement, potentially helping doctors make better-informed treatment decisions.
Three Antidepressants Show Promising Results antidepressant
The systematic review, published in The Lancet Psychiatry, analyzed 115 randomized controlled trials involving more than 30,000 participants. Researchers found that three medications demonstrated higher odds of sustained depression improvement compared with fluoxetine.
Escitalopram showed the strongest results, with 62% higher odds of sustained response. Duloxetine demonstrated 57% higher odds, while agomelatine showed 40% higher odds compared with the reference medication.
These findings suggest that the three medications could be useful options for certain patients requiring long-term depression treatment. However, researchers emphasized that medication effectiveness can vary depending on individual health conditions, symptoms, and treatment history.
Understanding the Benefits of Each Medication antidepressant
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for depression and anxiety disorders. It works by increasing serotonin availability in the brain. According to the research findings, it demonstrated the strongest long-term response among the three medications.
Duloxetine belongs to a class of medications known as serotonin-norepinephrine reuptake inhibitors (SNRIs). It affects both serotonin and norepinephrine levels and may also help people experiencing certain types of chronic pain alongside depression.
Agomelatine works differently by influencing melatonin receptors and serotonin activity. Its effects on sleep-wake rhythms may make it an option worth considering for some people with depression-related sleep disturbances. However, its potential effects on liver function require careful medical monitoring.
Why Long-Term Depression Treatment Matters
Depression can be a persistent condition that affects emotional well-being, sleep, concentration, relationships, and everyday activities. Although many people experience improvements with antidepressants, maintaining those improvements over time remains an important treatment goal.
Finding medications that support sustained recovery can help reduce the risk of symptoms returning. The latest findings provide additional evidence for doctors evaluating different treatment approaches, particularly when patients do not respond adequately to their initial medication.
The researchers’ comparison also highlights why long-term treatment outcomes deserve attention alongside short-term symptom improvement.
Safety and Individual Treatment Decisions Remain Important
Despite the promising findings, the three antidepressants are not suitable for everyone. Each medication has potential side effects and medical considerations that healthcare professionals must evaluate before prescribing treatment.
For example, duloxetine may not be appropriate for people with severely impaired kidney function. Escitalopram requires caution in individuals with certain heart rhythm risks or medications that can prolong the QT interval. Agomelatine has been associated with rare but serious liver complications and requires appropriate liver monitoring.
Another important consideration is that agomelatine is not approved by the U.S. Food and Drug Administration (FDA), although it is available in some other countries.
Mental health specialists emphasize that antidepressant selection should consider a person’s medical history, existing medications, symptoms, and previous treatment response. Patients should not stop, switch, or change the dosage of prescribed antidepressants without consulting their healthcare professional.
What the Research Means for the Future of Depression Care
The findings could influence future discussions about depression treatment guidelines and long-term medication choices. Escitalopram, duloxetine, and agomelatine appear to offer promising results compared with fluoxetine in the analyzed studies.
However, the research does not establish one universally best antidepressant. More importantly, the findings provide doctors with additional information to consider when developing individualized treatment plans.
As research into mental health treatment continues, identifying effective long-term options remains essential for helping people manage depression and maintain a better quality of life.